SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.790
+0.050 (1.34%)
At close: Feb 19, 2026, 4:00 PM EST
3.940
+0.150 (3.96%)
After-hours: Feb 19, 2026, 5:10 PM EST
SAB Biotherapeutics Market Cap
SAB Biotherapeutics has a market cap or net worth of $180.1 million as of February 19, 2026. Its market cap has increased by 807.61% in one year.
Market Cap
180.10M
Enterprise Value
73.36M
1-Year Change
807.61%
Ranking
Category
Stock Price
$3.79
Market Cap Chart
Since February 9, 2021, SAB Biotherapeutics's market cap has increased from $130.75M to $180.10M, an increase of 37.74%. That is a compound annual growth rate of 6.58%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 18, 2026 | 178.05M | - |
| Dec 31, 2025 | 178.05M | 408.46% |
| Dec 31, 2024 | 35.02M | -44.79% |
| Dec 29, 2023 | 63.43M | 113.36% |
| Dec 30, 2022 | 29.73M | -91.24% |
| Dec 31, 2021 | 339.54M | 159.68% |
| Feb 9, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Molecular Partners AG | 175.36M |
| Cartesian Therapeutics | 174.74M |
| Karyopharm Therapeutics | 174.63M |
| Eledon Pharmaceuticals | 174.58M |
| Sagimet Biosciences | 174.31M |
| Editas Medicine | 173.27M |
| Zentalis Pharmaceuticals | 172.88M |
| Tiziana Life Sciences | 172.29M |